A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Recruiting
Location: See all (31) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have a body mass index (BMI) of:
‣ ≥30 kilogram per square meter (kg/m2) OR
⁃ ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
• Have at least one unsuccessful attempt to lose weight by dieting
Locations
United States
California
Artemis Institute for Clinical Research
RECRUITING
Riverside
Florida
JEM Research Institute
RECRUITING
Atlantis
Headlands Research Orlando
RECRUITING
Orlando
Care Access - Tamarac
RECRUITING
Tamarac
Illinois
Care Access - Arlington Heights
RECRUITING
Arlington Heights
Kentucky
L-MARC Research Center
RECRUITING
Louisville
Louisiana
IMA Clinical Research Monroe - Armand
RECRUITING
Monroe
Maryland
Pharmasite Research, Inc.
RECRUITING
Baltimore
Missouri
Clinical Research Professionals
RECRUITING
Chesterfield
Clinvest Headlands Llc
RECRUITING
Springfield
North Carolina
Trial Management Associates - Wilmington - Floral Parkway
RECRUITING
Wilmington
New Jersey
IMA Clinical Research Warren
RECRUITING
Warren Township
New York
IMA Clinical Research Manhattan
RECRUITING
New York
Texas
Cedar Health Research
RECRUITING
Dallas
Headlands Research-El Paso
RECRUITING
El Paso
Cedar Health Research - Euless
RECRUITING
Euless
Cedar Health Research - Fort Worth
RECRUITING
Fort Worth
Care Access - Houston
RECRUITING
Houston
IMA Clinical Research San Antonio
RECRUITING
San Antonio
Other Locations
United Kingdom
FutureMeds - Birmingham
RECRUITING
Birmingham
Layton Medical Centre
RECRUITING
Blackpool
Bradford on Avon Health Centre
RECRUITING
Bradford-on-avon
FutureMeds - Liverpool
RECRUITING
Bromborough
Cheadle Community Hospital
RECRUITING
Cheadle
HMC Health Group - Meadows Centre for Health
RECRUITING
Hounslow
St Bartholomew's Medical Centre
RECRUITING
Oxford
Atlantic Medical
RECRUITING
Penzance
The Adam Practice
RECRUITING
Poole
Woodstock Bower Surgery
RECRUITING
Rotherham
Rame Group Practice
RECRUITING
Torpoint
Albany House Medical Centre
RECRUITING
Wellingborough
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2025-11-17
Estimated Completion Date: 2027-07
Participants
Target number of participants: 250
Treatments
Experimental: Retatrutide Dose 1
Participants will receive retatrutide subcutaneously (SC)
Experimental: Retatrutide Dose 2
Participants will receive retatrutide SC
Placebo_comparator: Placebo
Participants will receive placebo SC
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company